346 related articles for article (PubMed ID: 16769377)
1. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP).
Schmidt B; Roberts RS; Fanaroff A; Davis P; Kirpalani HM; Nwaesei C; Vincer M;
J Pediatr; 2006 Jun; 148(6):730-734. PubMed ID: 16769377
[TBL] [Abstract][Full Text] [Related]
2. Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams.
Supapannachart S; Khowsathit P; Patchakapati B
J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S87-92. PubMed ID: 10730525
[TBL] [Abstract][Full Text] [Related]
3. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants.
Oh W; Poindexter BB; Perritt R; Lemons JA; Bauer CR; Ehrenkranz RA; Stoll BJ; Poole K; Wright LL;
J Pediatr; 2005 Dec; 147(6):786-90. PubMed ID: 16356432
[TBL] [Abstract][Full Text] [Related]
4. Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants?
Cordero L; Nankervis CA; Delooze D; Giannone PJ
J Perinatol; 2007 Mar; 27(3):158-63. PubMed ID: 17251986
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes.
Liebowitz M; Clyman RI
J Pediatr; 2017 Aug; 187():119-126.e1. PubMed ID: 28396025
[TBL] [Abstract][Full Text] [Related]
6. Treatment to prevent patency of the ductus arteriosus: beneficial or harmful?
Bose CL; Laughon M
J Pediatr; 2006 Jun; 148(6):713-4. PubMed ID: 16769371
[No Abstract] [Full Text] [Related]
7. Risk factors for bronchopulmonary dysplasia in very low birth weight newborns treated with mechanical ventilation in the first week of life.
Cunha GS; Mezzacappa-Filho F; Ribeiro JD
J Trop Pediatr; 2005 Dec; 51(6):334-40. PubMed ID: 15927945
[TBL] [Abstract][Full Text] [Related]
8. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus.
Fujii AM; Brown E; Mirochnick M; O'Brien S; Kaufman G
J Perinatol; 2002; 22(7):535-40. PubMed ID: 12368968
[TBL] [Abstract][Full Text] [Related]
9. Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants.
Gudmundsdottir A; Johansson S; Håkansson S; Norman M; Källen K; Bonamy AK
Neonatology; 2015; 107(2):87-92. PubMed ID: 25412681
[TBL] [Abstract][Full Text] [Related]
10. [Prevalence and risk factors of bronchopulmonary dysplasia among extremely low birth weight newborns of regional birth cohort of south-east Poland].
Kwinta P; Grudzień A; Pawlik D; Olechowski W; Lauterbach R; Pietrzyk JJ
Przegl Lek; 2009; 66(1-2):14-20. PubMed ID: 19485250
[TBL] [Abstract][Full Text] [Related]
11. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms.
Alfaleh K; Smyth JA; Roberts RS; Solimano A; Asztalos EV; Schmidt B;
Pediatrics; 2008 Feb; 121(2):e233-8. PubMed ID: 18245398
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patent ductus arteriosus and neonatal mortality/morbidities: adjustment for treatment selection bias.
Mirea L; Sankaran K; Seshia M; Ohlsson A; Allen AC; Aziz K; Lee SK; Shah PS;
J Pediatr; 2012 Oct; 161(4):689-94.e1. PubMed ID: 22703954
[TBL] [Abstract][Full Text] [Related]
13. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants.
Stephens BE; Gargus RA; Walden RV; Mance M; Nye J; McKinley L; Tucker R; Vohr BR
J Perinatol; 2008 Feb; 28(2):123-8. PubMed ID: 18046337
[TBL] [Abstract][Full Text] [Related]
14. Retrospective economic evaluation of a controlled trial of indomethacin prophylaxis for patent ductus arteriosus in premature infants.
Zupancic JA; Richardson DK; O'Brien BJ; Cronin CG; Schmidt B; Roberts R; Weinstein MC;
Early Hum Dev; 2006 Feb; 82(2):97-103. PubMed ID: 16469456
[TBL] [Abstract][Full Text] [Related]
15. [Patent ductus arteriosus in premature infants].
Bratlid D; Farstad T
Tidsskr Nor Laegeforen; 2009 Aug; 129(15):1455-8. PubMed ID: 19690594
[TBL] [Abstract][Full Text] [Related]
16. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.
Kabra NS; Schmidt B; Roberts RS; Doyle LW; Papile L; Fanaroff A;
J Pediatr; 2007 Mar; 150(3):229-34, 234.e1. PubMed ID: 17307535
[TBL] [Abstract][Full Text] [Related]
17. Intrauterine inflammation as a risk factor for persistent ductus arteriosus patency after cyclooxygenase inhibition in extremely low birth weight infants.
Kim ES; Kim EK; Choi CW; Kim HS; Kim BI; Choi JH; Park JS; Moon KC
J Pediatr; 2010 Nov; 157(5):745-50.e1. PubMed ID: 20598319
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes.
Laughon M; Bose C; Clark R
J Perinatol; 2007 Mar; 27(3):164-70. PubMed ID: 17251985
[TBL] [Abstract][Full Text] [Related]
19. The effects of indomethacin tocolysis on the postnatal response of the ductus arteriosus to indomethacin in extremely low birth weight infants.
Cordero L; Nankervis CA; Gardner D; Giannone PJ
J Perinatol; 2007 Jan; 27(1):22-7. PubMed ID: 17053778
[TBL] [Abstract][Full Text] [Related]
20. [Is it possible to predict the success of pharmacological closure of persistent ductus arteriosus in prematurely born neonates?].
Fendler W; Bernas S; Jarosik K; Piotrowski A
Anestezjol Intens Ter; 2008; 40(3):156-61. PubMed ID: 19469116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
